Efficacy of AYUSH-64 (a polyherbal formulation) in COVID - 19 Cases

A Pilot Study To Assess The Efficacy Of AYUSH - 64 In COVID - 19 Cases

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/05/025335

Enrollment

Registered

2020-05-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Ayush-64, a polyherbal formulation. : The composition of AYUSH 64 includes aqueous extract of Saptaparna (Alstoniascholaris R. Br.) Katuki (Picrorhizakurroa Royle ex. Benth), Kiratatikt

Eligibility

Inclusion criteria

Inclusion criteria: Mild to moderate cases registered in CHC CBPACS above 18 years of age, with COVID 2019 (Confirmed by RT-PCR) Participants who can take medicines orally Patients willing to provide signed informed consent

Exclusion criteria

Exclusion criteria: Cases of severe vomiting which would make oral administration of medicine difficult. Cases of respiratory failure and requiring mechanical ventilation. Alanine Transaminase (ALT) or Aspartate Transaminase (AST) > 2 times the upper limit of normal. Patients with COVID 19 in critical condition or ARDS or NIAD 8 â??point ordinal score 2 Hospitalized, on invasive mechanical Ventilation or extra corporeal membrane oxygenation Pregnant or lactating women Any other condition, which as per the investigator would jeopardize the outcome of the trial.

Design outcomes

Primary

Measure	Time frame
a) Mean time (days) for clinical recovery as per clinical recovery criteria defined below b) Number of patients showing â??clinical recoveryâ?? Timepoint: Baseline Day 8 Day 15	—

Secondary

Measure	Time frame
1.Percentage of patients with negative SARS-CoV-2 on nasal or throat swab in a 2 day continuous real time RT-PCR test. 2.Improvement in selected laboratory parameters:, differential and total leukocyte counts, acute phase reactants, serum IL-6, Serological Protective Antibody Assay (IgE ,IgM and IgG) 3.Changes in liver enzymes, Renal functions 4.No of cases Reporting any ADR/AE 5.Number of participants referred with onset of complications Timepoint: Baseline 8th day 15th day	—

Measure

Time frame

1.Percentage of patients with negative SARS-CoV-2 on nasal or throat swab in a 2 day continuous real time RT-PCR test. 2.Improvement in selected laboratory parameters:, differential and total leukocyte counts, acute phase reactants, serum IL-6, Serological Protective Antibody Assay (IgE ,IgM and IgG) 3.Changes in liver enzymes, Renal functions 4.No of cases Reporting any ADR/AE 5.Number of participants referred with onset of complications Timepoint: Baseline 8th day 15th day

—

Countries

India

Contacts

Public ContactDr N R Singh

Chaudhary Bahm Prakash Ayurved Charak Sansthan, New Delhi

addl.director.academics@gmail.com9560659728

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026